12:00 AM
Aug 10, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Opaxio paclitaxel poliglumex: Phase I data

Data from an open-label, dose-escalation Phase I trial in 12 patients showed that Opaxio in combination with Alimta pemetrexed produced 9 cases of stable disease and led to a median progression-free survival (PFS) of 3.3 months. Patients received...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >